The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...

Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft ...

FAP is a transmembrane protein expressed on both cancer-associated fibroblasts and on normal activated fibroblasts involved in wound healing and tissue repair. FAP has long been a target for ...

Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

FAP is a transmembrane protein expressed on both cancer-associated fibroblasts and on normal activated fibroblasts involved in wound healing and tissue repair.

Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue ...